Your browser does not support JavaScript!
http://iet.metastore.ingenta.com
1887

Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy

Mathematical modelling of toxicity-related trade-offs in metronomic chemotherapy

For access to this article, please select a purchase option:

Buy article PDF
£12.50
(plus tax if applicable)
Buy Knowledge Pack
10 articles for £75.00
(plus taxes if applicable)

IET members benefit from discounts to all IET publications and free access to E&T Magazine. If you are an IET member, log in to your account and the discounts will automatically be applied.

Learn more about IET membership 

Recommend Title Publication to library

You must fill out fields marked with: *

Librarian details
Name:*
Email:*
Your details
Name:*
Email:*
Department:*
Why are you recommending this title?
Select reason:
 
 
 
 
 
IET Systems Biology — Recommend this title to your library

Thank you

Your recommendation has been sent to your librarian.

For better quality of life (QoL) for the cancer patients, metronomic chemotherapy (MCT) would be the rational option instead of conventional chemotherapy. However, in view of the recent arguments regarding the accumulation of toxicity in MCT, it is worthwhile to examine the role of pathophysiological constraints in retarding the curative potential of MCT. Drug application is stopped upon attaining a certain high level of toxicity and subsequent resumption is possible once the toxicity drops below a certain low level. Large delays in subsequent drug administration can thus effectively handle toxicity and it may retard the therapeutic potential due to excessive tumour growth in the absence of drug. Small delays, on the other hand, may result in inoperable pathophysiological states resulting in poor QoL. It is argued that only the intervention of domain knowledge of an expert oncologist with respect to drug administration decision can in fact clinch the trade-off issues arising out of the situation in favour of a sustainable QoL. A mathematical model that may act as a general guideline to tackle the trade-off issues in cancer treatment is provided. Rigorous simulation exercises are required to establish the concept of MCT in the backdrop of conventional cancer treatment practices.

References

    1. 1)
      • R.S. Kerbel , B.A. Kamen . The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer , 423 - 436
    2. 2)
      • H. Kitano . Cancer as a robust system: implications for anticancer therapy. Nat. Rev. Cancer , 227 - 235
    3. 3)
      • M.L. Kothari , L.A. Mehta . (1994) The other face of cancer.
    4. 4)
      • U. Emmenegger , G.C. Morton , G. Francia , Y. Shaked , M. Franco , A. Weinerman , S. Man , R.S. Kerbel . Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. , 1664 - 1674
    5. 5)
      • Q. Zhou , P. Guo , X. Wang , S. Nuthalapati , J. Gallo . Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens’ Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens'. J. Pharmacol. Exp. Ther. , 265 - 275
    6. 6)
      • P. Correale , D. Cerretani , C. Remondo , I. Martellucci , S. Marsili , M. La Placa , A. Sciandivasci , L. Paolelli , A. Pascucci , M. Rossi , M. Di Bisceglie , G. Giorgi , G. Gotti , G. Francini . A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol. Rep. , 133 - 140
    7. 7)
      • S.A. Bustin , T. Nolan . Pitfalls of quantitative real time reverse transcription polymerase chain reaction. J. Biomol. Tech. , 155 - 166
    8. 8)
      • L. Repetto . Greater risks of chemotherapy toxicity in elderly patients with cancer. J. Support. Oncol. , 18 - 24
    9. 9)
      • G.K. Ellis , R.B. Livingstone , J.R. Gralow , S.J. Green , T. Thomson . Dose dense anthracycline based chemotherapy for node positive breast cancer. J. Clin. Oncol. , 3637 - 3643
    10. 10)
      • B.K. Rothman . (1998) Writing the body: genetics of illness’, ‘Genetic maps and human imaginations: the limits of science in understanding who we are.
    11. 11)
      • V.T. DeVita , S. Hellman , S.A. Rosenberg . Cancer: principles and practice of oncology.
    12. 12)
      • Y.B. Su , S. Sohn , S.E. Krown , P.O. Livingston , J.D. Wolchok , C. Quinn , L. Williams , T. Foster , K.A. Sepkowitz , P.B. Chapman . Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J. Clin. Oncol. , 1 - 7
    13. 13)
      • A. Tulpule , J. Groopman , M.W. Saville , W. Harrington , A. Friedman-Kien , B.M. Espina , C. Garces , L. Mantelle , K. Mettinger , D.T. Scadden , P.S. Gill . Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer , 147 - 154
    14. 14)
      • P. Hahnfeldt , J. Folkman , L. Hlatky . Minimizing long term tumour burden: The logic for metronomic chemotherapeutic dosing and its anti-angiogenic basis. J. Theor. Biol. , 545 - 554
    15. 15)
      • G. Klement , S. Baruchel , J. Rak , S. Man , K. Clark , D.J. Hicklin , P. Bohlen , R.S. Kerbel . Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J. Clin. Invest. , R15 - R24
    16. 16)
      • D. Driankov , H. Hellendoorn , M. Reinfrank . (1997) An introduction to fuzzy control.
    17. 17)
      • S. Ben-Efraim . Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr. Drug Targets , 197 - 212
    18. 18)
      • S. Gately , R. Kerbel . Anti-angiogenic scheduling of lower dose cancer chemotherapy. Cancer J. , 427 - 436
    19. 19)
      • A.H. Filipovich , B.D. Spector , J. Kersey . Immunodeficiency in humans as a risk factor in development of malignancy. Prev. Med. , 252 - 259
    20. 20)
      • J. Crawford , D.C. Dale , G.H. Lyman . Chemotherapy induced neutropenia: risks, consequences and new directions for its managements. Cancer , 228 - 237
    21. 21)
      • D. Majumder , A. Mukherjee . Patho-physiologically based logistics for treatment of cancer. J. Biol. Syst. , 631 - 650
    22. 22)
      • H. Kaur , T. Budd . Metronomic therapy for breast cancer. Curr. Oncol. Rep. , 49 - 52
    23. 23)
      • B.A. Chabner , D.L. Longo . Cancer chemotherapy and biotherapy.
    24. 24)
    25. 25)
      • J. Lei , M.C. Mackey . Stochastic differential delay equation, moment stability, and application to the hematopoietic stem cell regulation system. SIAM J. Appl. Math. , 387 - 407
    26. 26)
      • Dasgupta, S.: `Political economy of (breast) cancer', Silver Jubilee of Indian Social Science Congress, 2002, 2002, Allahabad, India, Indian Academy of Social Sciences.
    27. 27)
      • S. Man , G. Bocci , G. Francis , S.K. Green , S. Jothy , D. Hanahan , P. Bohlen , D.J. Hicklin , G. Bergers , R.S. Kerbel . Antitumour effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. , 2731 - 2735
    28. 28)
      • A. Mukherjee , D. Majumder , A. Icbal . Exploring the effectiveness of low continuous chemo-bio-therapeutic treatment of cancer through analytical system modeling. J. Biol. Syst. , 1 - 12
    29. 29)
      • D. Kaplan , L. Glass . (1995) One-dimensional differential equations’, ‘Understanding nonlinear dynamics.
    30. 30)
      • M.A. O'Malley , J. Dupre . Fundamental issues in systems biology. BioEssays , 1270 - 1276
    31. 31)
      • E.F. Keller . The century beyond the gene. J Biosci. , 3 - 10
    32. 32)
      • M.L. Kothari , L.A. Mehta . Qualtum cosmics and chaotics – the ultimate tortoise in physics and modern medicine. J. Postgrad. Med. , 85 - 92
    33. 33)
      • B.R. Stoll , C. Migliorini , A. Kadambi , L. Munn , R.K. Jain . A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumours: implications for antiangiogenic therapy. Blood , 2555 - 2561
    34. 34)
      • A. Bottini , D. Generali , M.P. Brizzi , S.B. Fox , A. Bersiga , S. Bonardi , G. Allevi , S. Aguggini , G. Bodini , M. Milani , R. Dionisio , C. Bernardi , A. Montruccoli , P. Bruzzi , A.L. Harris , L. Dogliotti , A. Berruti . Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol. , 3623 - 3628
    35. 35)
      • V. Bhatt , A. Saleem . Drug induced neutropenia – pathophysiology, clinical features and management. Annl. Clin. Lab. Sci. , 131 - 137
    36. 36)
      • Majumder, D., Mukherjee, A.: `Simulation of drug administration delay in metronomic chemotherapy of cancer due to pathophysiological constraints', Proc. First Int. Conf. Comput. Systems Biol., 2006, Shanghai, China, p. 68–73, [ICCSB 2006 website contains presentation details].
    37. 37)
      • C. Folkins , S. Man , P. Xu , Y. Shaked , D.J. Hicklin , R.S. Kerbel . Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. , 3560 - 3564
    38. 38)
      • J.J. Hornberg , F.J. Bruggeman , H.V. Westerhoff , J. Lankelma . Cancer: a systems biology disease. Biosystems , 81 - 90
http://iet.metastore.ingenta.com/content/journals/10.1049/iet-syb_20060085
Loading

Related content

content/journals/10.1049/iet-syb_20060085
pub_keyword,iet_inspecKeyword,pub_concept
6
6
Loading
This is a required field
Please enter a valid email address